Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Panbela Therapeutics (PBLA)
OTHER OTC:PBLA
Panbela Therapeutics (PBLA) Stock Price & Analysis
225 Followers
PBLA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.41 - $477.00
Previous Close$0.49
Volume66.29K
Average Volume (3M)725.65K
Market Cap
$2.38M
Enterprise Value$4.99M
Total Cash (Recent Filing)$2.58M
Total Debt (Recent Filing)$5.19M
Price to Earnings (P/E)0.0
Beta-0.14
Next Earnings
May 14, 2024EPS Estimate
-$1.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-632.34
Shares Outstanding4,854,861
10 Day Avg. Volume66,536
30 Day Avg. Volume725,652
Standard Deviation0.37
R-Squared0.01
Alpha-0.10
Financial Highlights & Ratios
Price to Book (P/B)-0.54
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.23
Forecast
1Y Price Target
$5.00Price Target Upside921.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Panbela Therapeutics News
PremiumCompany Announcements
Panbela Therapeutics Updates ASPIRE Trial Timeline
PremiumCompany Announcements
Panbela Therapeutics Shifts from Nasdaq to OTCQB Market
PremiumPress Releases
Panbela Announces Transfer to OTCQB Market
Bulls Say, Bears Say
Bulls Say
Clinical Trial MilestoneThe Phase 3 'Prevention of Adenomas and Cancer with eflornithine and sulindac' (PACES) trial recently passed a single pre-planned futility analysis
Data ReadoutsMultiple data readouts could be a potential catalyst for the stock
FundingSecured funding for its robust number of clinical trials
Bears Say
Clinical TrialsInterim data for the Phase 3 clinical trial, ASPIRE, has been delayed
Financial StabilityCompany needs to raise additional funds to remain financially viable
Stock Price TargetTarget adjusted downward to $5
---
Ownership Overview
42.53% Insiders
0.09% Mutual Funds
0.00% Other Institutional Investors
57.38% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PBLA FAQ
What was Panbela Therapeutics’s price range in the past 12 months?
Panbela Therapeutics lowest stock price was $0.41 and its highest was $477.00 in the past 12 months.
What is Panbela Therapeutics’s market cap?
Currently, no data Available
When is Panbela Therapeutics’s upcoming earnings report date?
Panbela Therapeutics’s upcoming earnings report date is May 14, 2024 which is in 16 days.
How were Panbela Therapeutics’s earnings last quarter?
Panbela Therapeutics released its earnings results on Mar 26, 2024. The company reported -$65.9 earnings per share for the quarter, missing the consensus estimate of -$24.34 by -$41.56.
Is Panbela Therapeutics overvalued?
According to Wall Street analysts Panbela Therapeutics’s price is currently Undervalued.
Does Panbela Therapeutics pay dividends?
Panbela Therapeutics does not currently pay dividends.
What is Panbela Therapeutics’s EPS estimate?
Panbela Therapeutics’s EPS estimate is -$1.62.
How many shares outstanding does Panbela Therapeutics have?
Panbela Therapeutics has 4,854,861 shares outstanding.
What happened to Panbela Therapeutics’s price movement after its last earnings report?
Panbela Therapeutics reported an EPS of -$65.9 in its last earnings report, missing expectations of -$24.34. Following the earnings report the stock price went up 4.688%.
Which hedge fund is a major shareholder of Panbela Therapeutics?
Currently, no hedge funds are holding shares in PBLA
---
Panbela Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (921.45% Upside)
$5.00 (921.45% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 7.6%
Last 30 Days ▼ 7.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-99.84%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
137.08%
Trailing 12-Months
Company Description
Panbela Therapeutics
Sun BioPharma Inc. is a clinical-stage drug development company, which engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The company was founded by Michael Cullen and Thomas Neenan on September 21, 2011 and is headquartered in Waconia, MN.
---
PBLA Earnings Call
Q4 2024
0:00 / 0:00
---
PBLA Stock 12 Months Forecast
Average Price Target
$5.00
▲(921.45% Upside)
Technical Analysis
Best Analysts Covering PBLA
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-87.25%
reiterated a buy rating 27 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -87.25% per trade.
---